Immunotherapeutic interventions also hold potential: immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 can promote immune clearance of dormant tumor cells [145], while Chimeric Antigen Receptor (CAR) T cell or Natural Killer (NK)-based therapies directed against dormancy-associated antigens represent emerging strategies for selective eradication [146]. This evidence concerns the gene CD274 and neoplasm.